7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 2003-09-30 2003-06-30 2003-03-31 2002-03-31 2001-09-30 
      
    		                                                                                    
      cash flows from operating activities:
    		                                                                                    
      net income
    		-19,594,000 -1,185,000 -101,215,000 -864,585,000 -38,236,000 -15,808,000 -110,228,000 -49,766,000 794,000 -81,026,000 -74,151,000 -127,745,000 -148,761,000 -166,063,000 -180,937,000 -220,611,000 -166,938,000 -176,912,000 -31,164,000 -436,810,000 -219,884,000 -86,142,000 -105,697,000 77,945,000 -40,459,000 -38,420,000 -83,059,000 -53,974,000 -45,364,000 -36,387,000 -39,424,000 -21,764,000 -26,897,000 -30,790,000 -34,946,000 -37,170,000 -37,803,000 -44,765,000 -47,473,000 -39,991,000 -42,945,000 -39,066,000 -35,801,000 -32,444,000 -32,060,000 -19,437,000 -16,107,000 -11,160,000 -12,314,000 -10,854,000 -12,952,000 -14,836,000 -10,645,000 -7,773,000 -6,625,000 -4,373,000 -3,382,000 -2,477,000 -2,124,000 -1,041,000 -2,394,000 -3,839,000 -3,014,000 -2,100,000 -2,518,000 -4,195,000 -1,825,000 -1,920,000 -2,423,000 -3,083,000 -3,246,000 -4,163,000 11,810,480 -3,289,000 -3,951,000 -4,585,000 -4,403,000 -4,279,000 -5,291,000 -6,862,000 -7,884,000 -7,883,000 -7,585,885 -5,729,378 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                                                    
      depreciation
    		31,708,000 31,097,000 29,960,000 29,046,000 30,336,000 29,687,000 30,632,000 30,861,000 29,262,000 27,510,000 26,815,000 26,567,000 25,043,000                                                         89,000 101,000 198,000 -597,250 162,000 226,000 210,000 276,000 299,000 336,000 619,000 434,000 469,000   
      (gain) loss on non-marketable and marketable equity securities
    		                                                                                    
      deferred tax expense
    		501,000 -6,000 -1,007,000  -398,000 428,000 1,797,000   -589,000 1,261,000                                                                          
      stock-based compensation
    		51,623,000 55,783,000 54,618,000 49,203,000 48,757,000 56,555,000 60,370,000 58,577,000 61,871,000 61,725,000 49,139,000 45,917,000 49,533,000 58,932,000 52,441,000 55,883,000 63,603,000 56,285,000 77,292,000 41,831,000 41,476,000 40,039,000 29,560,000 47,826,000 24,348,000 20,143,000 16,166,000 15,710,000 16,498,000 15,593,000 12,463,000 12,510,000 10,778,000 6,095,000 6,129,000 6,959,000 6,166,000 4,507,000 6,100,000 4,902,000 4,980,000 4,548,000 3,620,000 2,877,000 4,165,000 2,483,000 1,995,000 1,849,000 2,856,000 955,000 1,565,000 1,424,000 1,035,000 1,101,000 1,068,000 686,000 640,000 508,000 527,000 624,000 711,000 623,000 265,000 229,000 301,000 1,376,000 720,000 409,000 561,000 668,000 710,000 1,067,000 -273,495 -81,000        328,000   
      gain on settlements of convertible notes
    		    0    0 0 -10,324,000                                                                          
      amortization of acquired intangible assets
    		24,174,000 24,186,000 24,101,000 24,101,000 24,435,000 23,311,000 23,311,000 23,311,000 22,992,000 22,929,000 22,928,000 22,914,000 23,526,000 26,356,000 24,654,000 24,047,000 23,940,000 23,824,000 23,190,000  23,430,000 23,430,000 23,339,000                                                              
      impairment of long-lived and indefinite-lived assets
    		543,000 0 6,251,000                                                                                  
      gain on contingent consideration from sale of asset
    		       -4,400,000                                                                             
      remeasurement of contingent consideration liabilities
    		8,705,000 4,909,000 8,287,000 -1,020,000 5,310,000 -13,239,000 5,603,000 -4,993,000                                                                             
      non-cash lease expense
    		6,765,000 6,730,000 6,753,000 6,281,000 6,603,000 6,990,000 7,052,000 6,973,000 7,141,000 6,971,000 6,806,000 4,187,000 7,171,000 9,918,000 7,363,000 7,478,000 6,510,000 6,097,000 5,740,000 4,679,000 4,181,000 -3,330,000 10,190,000 2,746,000 919,000 917,000 845,000                                                          
      other
    		2,873,000 3,993,000 2,001,000 918,000 1,230,000 -2,896,000 229,000 -3,131,000 -435,000                                                                            
      changes in assets and liabilities:
    		                                                                                    
      accounts receivable
    		46,853,000 -73,014,000 -30,072,000 15,151,000 -509,000 -23,365,000 -37,536,000 -3,110,000 -19,814,000 4,942,000 -25,434,000 33,120,000 -2,664,000 19,612,000 11,020,000 39,188,000 -23,033,000 31,945,000 -22,950,000 -26,884,000 -42,998,000 -24,322,000 -6,322,000 8,933,000 -18,297,000 -6,718,000 -11,856,000 -1,795,000 -5,648,000 -1,693,000 -8,156,000 -1,866,000 -1,598,000 -6,377,000 -7,688,000 -663,000 -422,000 -1,820,000 -688,000 -724,000 -2,058,000 -570,000 -205,000                                          
      inventory
    		6,713,000 5,106,000 -14,175,000 -25,395,000 -9,612,000 1,161,000 -1,065,000 5,384,000 -543,000 -6,704,000 -5,827,000 -3,526,000 473,000 -2,214,000 -7,964,000 -8,130,000 -5,358,000 1,035,000 3,232,000 -11,838,000 1,788,000 -12,791,000 -7,469,000 -4,516,000 -5,892,000 -3,512,000 -5,121,000 -139,000 -3,208,000 -3,029,000 -6,353,000 -7,963,000 -5,654,000 -4,551,000 -1,026,000 833,000 738,000 -247,000 -1,480,000 -645,000 243,000 -852,000 -1,406,000                                          
      operating lease liabilities
    		-7,276,000 -7,266,000 -6,575,000 -6,438,000 -6,388,000 -6,354,000 -6,603,000 -6,960,000 -6,975,000 -6,784,000 -5,982,000 -4,404,000 -5,574,000 -5,491,000 -5,177,000 -4,851,000 -4,739,000 -3,975,000 -3,120,000 -2,649,000 -1,138,000 -2,787,000 -2,210,000                                                              
      accounts payable and accrued liabilities
    		67,135,000 39,415,000 58,633,000 5,280,000 56,123,000 35,650,000 -53,515,000 31,666,000 2,330,000 53,571,000 -4,817,000 37,088,000 -9,929,000 -13,291,000 -66,048,000 105,456,000 37,206,000 43,000,000 -15,862,000 62,773,000 39,979,000 -29,291,000 -18,296,000                                                              
      other assets
    		7,407,000 8,624,000 -3,837,000 -8,681,000 3,639,000 9,305,000 -6,586,000 -7,932,000 5,938,000 3,998,000 -13,622,000                                                                          
      other liabilities
    		-626,000 -7,219,000 -5,814,000 -1,389,000 1,174,000 12,845,000 -2,904,000 7,607,000 -5,508,000 5,395,000 -1,161,000                                                                          
      net cash from operating activities
    		219,923,000 89,017,000 30,809,000 47,063,000 138,719,000 107,065,000 -82,311,000 69,549,000 24,361,000 100,424,000 -38,215,000 52,037,000 -40,926,000 -60,916,000 -173,754,000 -24,572,000 -40,774,000 40,337,000 -77,227,000 111,404,000 81,775,000 -6,870,000 -49,827,000 -28,684,000 -29,080,000 17,161,000 -74,407,000 -1,236,000 -4,053,000 -25,514,000 -38,522,000 -764,000 -5,450,000 -31,872,000 -33,638,000 -27,129,000 -24,966,000 -35,624,000 -42,347,000 -33,804,000 -34,525,000 -31,187,000 -34,501,000                                          
      capex
    		-29,897,000 -42,342,000 -31,174,000 -36,316,000 -26,158,000 -35,866,000 -37,649,000 -34,922,000 -25,187,000 -34,721,000 -29,360,000 -72,876,000 -44,637,000 -63,326,000 -33,623,000 -59,392,000 -38,870,000 -24,584,000 -12,920,000 -16,570,000 -14,327,000 -20,770,000 -12,685,000 -40,832,000 -51,522,000 -68,791,000 -10,657,000 -52,106,000 -53,623,000 -29,036,000 -15,328,000 -24,038,000 -15,794,000 -5,903,000 -2,745,000 -2,685,000 -5,751,000 -4,026,000 -2,389,000 -2,544,000 -6,798,000 -7,535,000 -3,207,000                                          
      free cash flows
    		190,026,000 46,675,000 -365,000 10,747,000 112,561,000 71,199,000 -119,960,000 34,627,000 -826,000 65,703,000 -67,575,000 -20,839,000 -85,563,000 -124,242,000 -207,377,000 -83,964,000 -79,644,000 15,753,000 -90,147,000 94,834,000 67,448,000 -27,640,000 -62,512,000 -69,516,000 -80,602,000 -51,630,000 -85,064,000 -53,342,000 -57,676,000 -54,550,000 -53,850,000 -24,802,000 -21,244,000 -37,775,000 -36,383,000 -29,814,000 -30,717,000 -39,650,000 -44,736,000 -36,348,000 -41,323,000 -38,722,000 -37,708,000                                          
      cash flows from investing activities:
    		                                                                                    
      purchases of marketable securities
    		-46,473,000 -13,481,000 -80,315,000 -59,646,000 -81,013,000 -147,047,000 -177,325,000 -64,758,000 -24,440,000 -42,067,000 -8,589,000 -29,048,000 -23,328,000 -8,843,000 -70,267,000 -142,493,000 -106,268,000 -752,791,000 -162,498,000 -199,941,000 -249,927,000 -214,917,000 -425,168,000 -29,988,000 -92,542,000 -248,700,000 -262,887,000 -110,844,000 -186,806,000 -266,354,000 -628,502,000 -12,012,000 -156,791,000 -157,685,000 -30,563,000 -38,533,000 -145,338,000 0 -6,118,000 -7,057,000 -178,679,000 -8,173,000 -11,145,000                                          
      maturities and sales of marketable securities
    		40,053,000 252,872,000 77,557,000 54,905,000 70,581,000 36,357,000 43,978,000 35,102,000 57,229,000 149,493,000 121,332,000  108,130,000 118,680,000 150,630,000  99,450,000 89,085,000 236,295,000  291,424,000 229,340,000 39,143,000                                                              
      purchases of property, plant and equipment
    		-29,897,000 -42,342,000 -31,174,000 -36,316,000 -26,158,000 -35,866,000 -37,649,000 -34,922,000 -25,187,000 -34,721,000 -29,360,000 -72,876,000 -44,637,000 -63,326,000 -33,623,000 -59,392,000 -38,870,000 -24,584,000 -12,920,000 -16,570,000 -14,327,000 -20,770,000 -12,685,000 -40,832,000 -51,522,000 -68,791,000 -10,657,000                                                          
      asset acquisition
    		                0 -33,073,000 -25,000,000                                                                  
      purchases of non-marketable investments
    		-50,289,000                                                                                    
      proceeds from contingent consideration receivable
    		0                                                                                    
      other investing activities
    		152,000 650,000 -505,000 0 -20,000 0 -205,000 500,000 250,000   -500,000 0 -42,000 -7,000 -500,000 0 -103,000 -141,000 -137,000 272,000 -186,000 -330,000                                                              
      net cash from investing activities
    		-86,454,000 224,895,000 -34,437,000 -41,872,000 -81,716,000 -147,129,000 -171,438,000 -66,767,000 -32,969,000 66,474,000 82,941,000 -58,159,000 65,005,000 21,659,000 45,561,000 78,437,000 -49,243,000 -793,767,000 -317,512,000 -306,638,000 16,828,000 -6,380,000 -405,847,000 -834,774,000 857,442,000 -102,672,000 -41,069,000 -9,417,000 -78,988,000 -130,778,000 -562,731,000 24,654,000 -126,596,000 -82,791,000 23,928,000 9,290,000 -105,280,000 31,298,000 53,173,000 40,956,000 -141,975,000 19,500,000 16,764,000    17,304,000   6,824,000             2,221,000 3,192,000 2,560,000 5,499,000 1,591,000 1,516,000 8,000 -3,209,000 6,104,000 1,622,000 -16,806,240 2,773,000 11,919,000 2,130,000    -7,968,000 9,837,000 2,568,000   
      cash flows from financing activities:
    		                                                                                    
      payments on settlement of convertible notes
    		0 0 -249,172,000                 0 0 0 -150,054,000 0 0 -1,000 -493,355,000                                                          
      proceeds from exercise of common stock options, net of cash paid for taxes
    		209,000 293,000 -422,000  2,132,000 43,000 -1,408,000                                                                              
      proceeds in connection with the company’s employee stock purchase plan
    		0    0    0    0    0    0                        0                                        
      payments on accounts receivable securitization facility
    		   0 0                                                                                
      proceeds from issuance of convertible notes
    		   0 0   0 0 0 137,976,000         0 0 0 1,125,547,000 0 -2,000 -57,000 729,536,000 -1,000 6,000 225,334,000 671,091,000                                                      
      payments on settlement of contingent consideration liabilities
    		0                                                                                    
      other financing activities
    		-1,741,000 -1,840,000 -6,577,000 -2,210,000 -2,358,000 -11,592,000 -1,594,000 -2,267,000 -985,000 -1,155,000 -5,344,000 -417,000 -706,000 -2,860,000 -1,547,000 -544,000 -1,674,000 -1,554,000 -1,514,000 -2,067,000 -312,000 -313,000 -313,000                                                              
      net cash from financing activities
    		-1,532,000 -4,514,000 -256,171,000 10,499,000 -226,000 224,603,000 -3,002,000 10,037,000 92,000 16,041,000 133,596,000 10,103,000 235,000 63,412,000 2,735,000 -12,196,000 81,000 13,342,000 7,245,000 879,859,000 4,158,000 16,124,000 979,480,000 6,624,000 980,000 5,451,000 240,126,000 9,354,000 19,074,000 233,277,000 672,437,000 2,718,000 2,460,000 255,775,000 3,000 3,366,000 144,706,000 1,267,000 247,000 2,509,000 174,166,000 4,795,000 295,000 105,865,000 136,000 138,025,000 2,000 636,000 73,616,000 8,000 57,981,000 222,000 1,642,000 331,000 211,000 14,000 1,434,000 17,743,000 1,109,000 804,000 8,071,000 22,614,000 100,000 0 6,000 117,000 0 15,000 354,000 48,000 18,000 53,000 -137,863 65,000 4,000 69,000 105,000 266,000 43,566,000 847,000 124,000 181,000 251,460 139,980 
      effects of exchange rate changes on cash and cash equivalents
    		1,000 574,000 290,000 -3,721,000 1,873,000 -306,000 -1,140,000 1,947,000 -1,235,000 59,000 550,000 3,206,000 -2,429,000 -510,000 -237,000          -66,000 -82,000 120,000 24,000 10,000 -18,000 20,000 46,000 16,000   -51,000                                                 
      net increase in cash, cash equivalents and restricted cash
    		131,938,000    58,650,000 184,233,000 -257,891,000 14,766,000 -9,751,000 182,998,000 178,872,000     41,692,000 -89,936,000 -740,088,000 -387,494,000 684,625,000 102,761,000 2,874,000 523,806,000                                                              
      cash, cash equivalents and restricted cash, beginning of period
    		0 0 606,636,000  0 0 609,675,000  0 0 242,790,000  0 0 315,768,000  0 0 1,491,594,000  0 0 177,528,000                                                              
      cash, cash equivalents and restricted cash, end of period
    		131,938,000 309,972,000 347,127,000  58,650,000 184,233,000 351,784,000  -9,751,000 182,998,000 421,662,000  21,885,000 23,645,000 190,073,000  -89,936,000 -740,088,000 1,104,100,000  102,761,000 2,874,000 701,334,000                                                              
      loss on non-marketable and marketable equity securities
    		 -2,136,000 2,900,000                                                                                  
      loss on contingent consideration from sale of asset
    		      268,000                                                                              
      net decrease in cash, cash equivalents and restricted cash
    		  -259,509,000          21,885,000 23,645,000 -125,695,000                                                                      
      (gain) loss on non-marketable and marketable equity investments
    		                                                                                    
      deferred tax benefit
    		       -676,000    -2,555,000 -4,406,000 -3,028,000 -1,912,000 -4,453,000 -4,207,000 -1,379,000 -243,130,000 -1,886,000 -4,754,000 -1,304,000 -1,918,000 -184,768,000 643,000 -464,000 -520,000     116,000                                                     
      gain on settlement of convertible notes
    		                                                                                    
      loss on sale of asset
    		           0                                                                         
      changes in assets and liabilities, net of effects of acquisition:
    		                                                                                    
      proceeds from sale of asset
    		           0                                                                         
      maturities and sales of investments in non-marketable securities
    		                                                                                    
      investments in non-marketable securities
    		                                                                                    
      business combination, net of cash acquired and issuance costs
    		           -15,371,000 0                                                                        
      asset acquisitions, net of cash acquired
    		                                                                                    
      proceeds from accounts receivable securitization facility
    		           0 0                                                                        
      proceeds from exercise of common stock options
    		       304,000 1,077,000 852,000 964,000 558,000 941,000 743,000 4,282,000 1,065,000 1,755,000 2,858,000 8,759,000 11,669,000 4,470,000 6,638,000 4,300,000 2,398,000 1,391,000 1,348,000 3,650,000 260,000 731,000 4,254,000 1,391,000 1,753,000 2,578,000 725,000 47,000 2,362,000 500,000 261,000 288,000 287,000 102,000 473,000 386,000 2,216,000 231,000 105,000 88,000                                      
      proceeds in connection with the company's employee stock purchase plan
    		                       4,259,000 0   2,232,000 2,000   1,212,000 0   1,051,000 1,000   960,000 1,000                                            
      net increase in cash, cash equivalents, and restricted cash
    		                                                                                    
      cash, cash equivalents, and restricted cash at the beginning of period
    		                                                                                    
      cash, cash equivalents, and restricted cash at the end of period
    		                                                                                    
      impairment of long-lived assets
    		    18,698,000 8,152,000 4,446,000 0 0 552,000 69,000 3,432,000                                                                         
      remeasurement of contingent consideration from sale of asset
    		    -3,100,000                                                                                
      business combination, net of cash acquired
    		               -84,181,000 0 -72,301,000 -343,248,000 0 -4,000 153,000 -6,807,000                                                              
      asset acquisition, net of cash acquired
    		                                                                                    
      purchases of non-marketable securities
    		                                                                                    
      sales of investments in non-marketable securities
    		                                                                                    
      loss on non-marketable and marketable equity investments
    		     -1,303,000 2,418,000                                                                              
      investments in privately held companies
    		      -237,000 -10,274,000 -117,000 -5,731,000 -442,000  -160,000 -25,495,000 -1,172,000  -3,555,000 0 -10,000,000                                                                  
      post-combination expense for acceleration of unvested equity
    		               0 0 0 80,960,000                                                                  
      asset acquisition ipr&d expense
    		               0 0 33,074,000 52,263,000                                                                  
      maturities and sales of investments in privately held companies
    		                                                                                    
      payments on construction loan
    		                                                                                    
      cash, cash equivalents and restricted cash at the beginning of period
    		                                                                                    
      cash, cash equivalents and restricted cash at the end of period
    		                                                                                    
      unrealized loss on equity investments
    		        5,523,000 7,090,000 3,009,000                                                                          
      realized (gain) loss on non-marketable investment
    		                                                                                    
      sales of investments in privately held companies
    		                                                                                    
      realized gain on non-marketable investment
    		                                                                                    
      remeasurement of contingent consideration
    		         4,250,000 -8,937,000 1,002,000 -5,860,000 -25,079,000 -26,680,000 -4,626,000 1,785,000 6,322,000 2,879,000                                                                  
      loss on disposal of property, plant and equipment
    		          284,000 -220,000 1,917,000 -155,000 321,000 127,000 289,000 302,000 337,000 1,540,000 280,000 378,000 272,000 514,000 669,000 129,000 82,000                                                          
      amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities
    		          1,783,000 1,854,000 1,853,000 1,720,000 1,700,000 1,735,000 1,666,000 1,649,000 1,633,000                                                                  
      accretion (amortization) of discount (premium) on short-term investments
    		          -54,000                                                                          
      unrealized (gain) loss on equity investments
    		             2,897,000 1,350,000 -445,000                                                                     
      realized (gain) loss on non-marketable investments
    		                                                                                    
      loss on settlement of convertible notes
    		                   0 0 0 7,954,000 0 0 0 10,558,000                                                          
      amortization of premium on short-term investments
    		           50,000 302,000 537,000 956,000  1,649,000 1,177,000 439,000  537,000 450,000 53,000 -213,000 -309,000 -1,274,000 -1,306,000 -1,320,000 -1,189,000 -877,000 -515,000 9,000 -1,000 20,000 37,000 51,000 66,000 132,000 214,000 303,000 318,000 325,000 377,000 214,000 258,000 225,000 145,000 188,000 130,000 140,000                                   
      other assets and liabilities
    		           6,079,000 -1,990,000 2,337,000 -7,834,000 -37,801,000 -20,040,000 -1,127,000 1,033,000 6,767,000 -8,460,000 52,857,000 -9,438,000                                                              
      maturities of marketable securities
    		                         215,059,000 232,615,000 171,884,000 161,445,000 164,681,000 81,161,000 75,981,000 49,010,000 89,239,000 57,236,000 50,508,000 45,809,000 35,324,000 61,680,000 52,457,000 43,502,000 35,208,000 31,116,000 26,483,000 32,921,000 20,349,000 24,419,000 15,421,000 13,636,000 16,431,000 15,251,000 10,238,000 16,334,000 4,752,000 11,128,000 1,498,000 1,672,000 3,670,000 1,756,000 11,974,000   2,243,000 4,213,000 5,080,000 7,868,000 7,226,000 8,850,000 7,871,000 9,671,000 11,397,000 7,361,000 -32,116,578 9,137,000 14,509,000 8,511,000         
      investment in privately held companies
    		                                                                                    
      proceeds from sale of common stock, net of issuance costs
    		                               -1,000 -74,000   -5,000    0    100,916,000 -6,000   -6,000         0   0                         
      realized (gain) loss on preferred stock investment
    		                                                                                    
      realized gain on preferred stock investment
    		               0 0 0 -30,500,000                                                                  
      intangible asset impairment charge
    		               0    0                                                                 
      depreciation and amortization
    		              22,993,000 21,078,000 22,260,000 21,499,000 20,508,000  19,713,000 17,626,000 16,006,000                                     18,000                       449,494 325,252 
      unrealized gain on equity investments
    		                 -2,479,000 -7,000                                                                  
      depreciation and other amortization
    		                                                                                    
      unrealized net (gain) loss on revaluation of equity securities
    		                                                                                    
      loss on preferred stock investment
    		                                                                                    
      amortization of convertible note debt discount and issuance costs
    		                   21,257,000 20,584,000 20,085,000 14,553,000                                                              
      amortization of deferred financing costs and other liabilities
    		                   -275,000 -1,109,000 -1,432,000 -1,073,000                                                              
      amortization of acquired intangibles
    		                                                                                    
      proceeds from construction loan, net deferred financing costs
    		                                                                                    
      unrealized loss on revaluation of marketable equity securities
    		                     -336,000 669,000                                                              
      proceeds from construction loan
    		                        0 24,000 295,000 6,989,000 16,174,000                                                        
      realized gain on sale of marketable securities
    		                       -15,000                                                             
      unrealized net income on revaluation of equity securities
    		                                                                                    
      amortization of liabilities
    		                       -32,123,000 9,173,000 10,063,000 8,420,000                                                          
      purchases of intangible assets
    		                                                                                    
      proceeds from financing obligation, net payments on mortgage payable
    		                                                                                    
      depreciation and amortization of property, plant and equipment
    		                        8,351,000 7,075,000 6,324,000                                                          
      amortization of intangible assets
    		                        811,000 805,000 810,000 755,000 619,000 616,000 612,000 410,000 355,000 240,000 50,000 50,000 50,000 50,000 50,000                                              
      accrued interest
    		                        -1,702,000 1,804,000 -3,106,000 2,692,000 -2,253,000 2,747,000 1,407,000         0 0 -112,000 6,000 6,000 5,000 5,000 6,000 6,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000                          
      prepaid expenses and other current assets
    		                        4,716,000 -730,000 -3,552,000 4,701,000 -7,367,000 -3,598,000 -2,812,000 396,000 -1,633,000 571,000 -329,000 -941,000 1,622,000 427,000 -347,000 -1,150,000 -1,616,000 73,000 -364,000                       75,000   131,000 378,000   -618,318            
      accounts payable
    		                        -738,000 2,344,000 -10,589,000 -5,271,000 21,746,000 -1,282,000 -3,861,000 7,361,000 6,495,000 1,346,000 181,000 -1,625,000 -800,000 294,000 -467,000 1,805,000 158,000 -656,000 -646,000 -1,988,000   570,000    263,000 -182,000 184,000    -182,000 272,000 134,000     75,000 30,000 103,000             129,000   229,000 354,772  
      accrued liabilities
    		                        -8,708,000 25,596,000 7,891,000 23,344,000 8,198,000 -9,175,000 -623,000 5,848,000 9,574,000 -1,472,000 1,204,000 1,896,000 2,802,000 3,315,000 -664,000 -381,000 4,624,000 4,654,000 -1,473,000                                          
      other short-term liabilities
    		                        112,000 144,000 -60,000 85,000 18,000 98,000 -29,000 148,000                                                     
      other long-term liabilities
    		                        -678,000 19,072,000 -2,092,000                                                          
      other long-term assets
    		                        1,301,000 -1,321,000 -22,734,000                                                          
      internally developed software
    		                        -150,000 -240,000 -140,000 -443,000 -4,000 -69,000 -62,000 -45,000                                                     
      proceeds from financing obligation
    		                           12,000                                                         
      payments of deferred financing costs
    		                           1,000 -1,000                                                        
      payments on mortgage payable
    		                           0 -4,588,000 -45,000 -45,000 -44,000 -44,000 -42,000 -44,000 -42,000 -42,000 -41,000 -41,000                                              
      stock issuance costs
    		                                                                                    
      ​
    		                                                                                    
      net increase in cash and cash equivalents
    		                        829,276,000 -80,142,000 124,770,000 -1,275,000 -63,957,000 76,967,000 71,204,000 26,654,000 -129,570,000 141,201,000 -9,715,000 -14,524,000 14,435,000 -3,141,000 11,016,000 9,613,000 -2,243,000 -6,914,000 -17,452,000 30,302,000 7,121,000 2,902,000 4,955,000             10,490,000   565,000           -501,000     9,979,000     -4,596,378 
      cash and cash equivalents, beginning of period
    		                        0 0 160,430,000 0 0 0 77,491,000 0 0 0 48,921,000 0 0 0 41,135,000 0 0 0 58,131,000 0 0 0 12,851,000 0 0 13,345,000 0 0 35,781,000 0 0 78,752,000 0 0 21,924,000 0 0 4,937,000 0 0 4,486,000 0 0 4,831,000  0 0 13,007,000 -13,078,908 0 0 13,092,000 0 0 14,200,000 0 0 17,439,000 56,842,722 0 
      cash and cash equivalents, end of period
    		                        829,276,000 -80,142,000 285,200,000 -1,275,000 -63,957,000 76,967,000 148,695,000 26,654,000 -129,570,000 141,201,000 39,206,000 -14,524,000 14,435,000 -3,141,000 52,151,000 9,613,000 -2,243,000 -6,914,000 40,679,000 30,302,000 7,121,000 2,902,000 17,806,000 -11,808,000 13,465,000 8,053,000 6,634,000 -6,266,000 12,292,000 -33,269,000 -33,809,000 72,073,000 -3,417,000 6,061,000 18,171,000 10,490,000 8,693,000 3,595,000 565,000 1,505,000 3,999,000 3,329,000 -17,000 3,852,000  -5,841,000 3,441,000 10,391,000 -17,110,993 -501,000 8,292,000 9,333,000 2,708,000 -10,334,000 24,179,000 1,369,000 2,953,000 11,783,000 50,195,303 -4,596,378 
      supplemental disclosure of non-cash investing and financing activities:
    		                                                                                    
      property, plant and equipment acquired but not paid
    		                        -7,469,000 -17,717,000 42,119,000                                                          
      unrealized gain on available-for-sale investments, before tax
    		                        -2,697,000 1,952,000 2,176,000                                                          
      issuance of 86,532 and 86,882 shares of common stock to fund the company’s 401(k) matching contribution for 2018 and 2017, respectively
    		                        0                                                            
      issuance of 2,159,017 shares of common stock upon settlement of convertible notes
    		                                                                                    
      retirement of equity component of convertible notes settled
    		                        0 0 -300,768,000                                                          
      interest paid
    		                        3,729,000 174,000 5,214,000 0 4,541,000 49,000 48,000 50,000 50,000 51,000 50,000 52,000 52,000 52,000 53,000                                              
      issuance of 2,158,991 shares of common stock upon settlement of convertible notes
    		                         0 182,435,000                                                          
      long-term obligations
    		                          18,492,000                                                          
      issuance of 86,532 and 86,828 shares of common stock to fund the company’s 401(k) matching contribution for 2018 and 2017, respectively
    		                          7,409,000                                                          
      depreciation and amortization of property and equipment
    		                           6,133,000 5,541,000                                                        
      loss on disposal of property and equipment
    		                           -500,000 757,000 -2,000 98,000 653,000 210,000 71,000 20,000 50,000 57,000           0 66,000 25,000                                   
      amortization of debt discount
    		                           7,732,000 7,737,000 6,171,000 4,651,000                                                      
      amortization of debt issuance costs
    		                           676,000 677,000 518,000 402,000                                                      
      amortization of other liabilities
    		                           -691,000 -673,000 -603,000 -533,000 -475,000 -430,000 -392,000 -377,000 -300,000 -268,000 -237,000 -208,000 -174,000 -158,000                                            
      amortization of deferred financing costs
    		                           20,000 37,000 26,000 23,000 14,000 14,000 12,000 14,000 12,000 14,000 13,000 13,000 11,000                                             
      proceeds from refundable tax credits
    		                                                                                    
      lease incentive obligation
    		                           -159,000 -179,000 836,000 -153,000 -154,000 -154,000 -154,000 -154,000 -153,000 -136,000 -153,000 130,000 -138,000 -139,000 -138,000 -138,000                                          
      purchases of property and equipment
    		                           -52,106,000 -53,623,000 -29,036,000 -15,328,000 -24,038,000 -15,794,000 -5,903,000 -2,745,000 -2,685,000 -5,751,000 -4,026,000 -2,389,000 -2,544,000 -6,798,000 -7,535,000 -3,207,000                                          
      business acquisition, net of cash acquired
    		                               16,000                                                     
      investment in privately-held company
    		                                                                                    
      payments on capital lease
    		                                                                                    
      property and equipment acquired but not paid
    		                           7,738,000 693,000 12,508,000 12,513,000 4,888,000 1,825,000 1,330,000 775,000 106,000 -506,000 21,000 1,034,000                                              
      property acquired under build-to-suit lease
    		                                                                                    
      unrealized loss on available-for-sale investments
    		                                                    -35,000                                
      issuance of 86,882, 158,717, and 341,507 shares of common stock to fund the company’s 401(k) matching contribution for 2017, 2016, and 2015, respectively
    		                                                                                    
      business acquisition contingent consideration liability
    		                                                                                    
      unrealized gain on available-for-sale investments
    		                              -1,606,000 -482,000 49,000   -180,000 -145,000 82,000 473,000 -540,000 75,000 -59,000 195,000 -109,000   8,000 33,000 14,000 -7,000 39,000    -11,000 -2,000 -18,000 -1,000 -1,000                          
      issuance of 86,882 and 158,717 shares of common stock to fund the company’s 401(k) matching contribution for 2017 and 2016, respectively
    		                            0                                                        
      depreciation and amortization of fixed assets
    		                              4,281,000 3,993,000 3,751,000 3,509,000 3,247,000 3,072,000 2,948,000 2,816,000 2,473,000 2,188,000 2,035,000 1,790,000 1,587,000                                          
      issuance of 86,828 and 158,717 shares of common stock to fund the company’s 401(k) matching contribution for 2017 and 2016, respectively
    		                              4,300,000                                                      
      forgiveness of long-term debt
    		                                       0 0                                            
      purchased intangible assets
    		                               -12,248,000                                                     
      payments on capital lease obligations
    		                                       0 -177,000 -92,000 -91,000                                          
      proceeds from mortgage payable
    		                                       1,306,000 100,000                                            
      issuance of 158,717, 341,507 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2016, 2015, and 2014 respectively
    		                                                                                    
      issuance of 158,717 and 341,507 shares of common stock to fund the company’s 401(k) matching contribution for 2016 and 2015, respectively
    		                                0 0 3,008,000                                                  
      amortization of deferred license fees
    		                                                                                    
      proceeds from new market tax credit financing agreements
    		                                                                                    
      issuance of 341,507, 21,826 and 32,666 shares of common stock to fund the company’s 401(k) matching contribution for 2015, 2014 and 2013, respectively
    		                                                                                    
      issuance of 341,507 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2015 and 2014, respectively
    		                                                                                    
      effects of exchange rate on cash and cash equivalents
    		                                     -82,000 -57,000 -48,000 91,000 -22,000 -10,000                                          
      issuance of 340,950 and 21,826 shares of common stock to fund the company’s 401(k) matching contribution for 2015 and 2014, respectively
    		                                     5,000 2,146,000                                              
      issuance of 21,826, 32,666 and 30,538 shares of common stock to fund the company’s 401(k) matching contribution for 2014, 2013 and 2012, respectively
    		                                                                                    
      issuance of 21,826 and 32,669 shares of common stock to fund the company’s 401(k) matching contribution for 2014 and 2013, respectively
    		                                        0                                            
      amortization of other long-term liabilities
    		                                          -58,000                                          
      issuance of 21,826 and 32,666 shares of common stock to fund the company’s 401(k) matching contribution for 2014 and 2013, respectively
    		                                          835,000                                          
      warrant licensing expense
    		                                                  0 125,000 27,000   27,000 26,000 27,000 27,000                          
      restricted stock licensing expense
    		                                                  0                                  
      accrued expenses
    		                                           2,832,000 2,568,000 1,754,000 1,456,000 1,498,000 1,143,000 372,000 355,000   429,000   207,000         516,000 258,000 38,000 289,000 -64,000       67,000 60,000 344,000    233,528 814,623 
      issuance of 32,666, 30,538, and 32,872 shares of common stock to fund the company’s 401(k) matching contribution for 2013, 2012, and 2011, respectively
    		                                                                                    
      laboratory equipment acquired with a capital lease
    		                                                                                    
      depreciation of property and equipment
    		                                               330,000 332,000 314,000 249,000 215,000 202,000 117,000 78,000 67,000 62,000                            
      issuance of 32,269 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively
    		                                                                                    
      depreciation of fixed assets
    		                                             688,000 656,000            48,000   12,000   59,000                    
      loss on disposal of fixed asset
    		                                                                                    
      issuance of 32,266 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively
    		                                                                                    
      issuance of 32,666 and 30,534 shares of common stock to fund the company’s 401(k) matching contribution for 2013 and 2012, respectively
    		                                              456,000                                      
      proceeds from exercise of common stock options and stock purchase plan
    		                                               726,000 396,000 90,000 226,000 222,000 1,642,000 331,000 211,000 14,000 0 146,000 147,000 704,000 9,000 14,000 0 0 6,000 17,000 0 15,000 134,000 48,000 18,000 53,000 -137,863 65,000 5,000 68,000 102,000 2,000 160,000 845,000 123,000 127,000   
      issuance of 30,534 and 32,872 shares of common stock to fund the company’s 401(k) matching contribution for 2012 and 2011, respectively
    		                                               0                                     
      conversion of accrued expenses into 34,442 and 34,336 shares of common stock in connection with the company’s employee stock purchase plan for 2013 and 2012, respectively.
    		                                               0                                     
      net decrease in cash and cash equivalents
    		                                                                                    
      issuance of 30,534 and 32,872 shares of common stock to fund the
    		                                                                                    
      company’s 401(k) matching contribution for 2012 and 2011, respectively
    		                                                 354,000                                   
      issuance of 32,872 and 27,872 shares of common stock to fund the company’s 401(k) matching contribution for 2011 and 2010, respectively
    		                                                  0 0 274,000                                
      conversion of accrued expenses into 34,336 and 27,110 shares of common stock in connection with the company’s employee stock purchase plan for 2012 and 2011, respectively
    		                                                  0                                  
      proceeds from genzyme collaboration, license and purchase agreement
    		                                                        934,000 0 962,000 0 0 16,650,000                       
      decrease in restricted cash
    		                                                                                    
      issuance of 27,872 and 15,460 shares of common stock to fund the company’s 401(k) matching contribution for 2010 and 2009, respectively
    		                                                     0 1,000 168,000                             
      amortization and write-offs of patents
    		                                                             95,000 5,000 281,000 34,000 110,000 68,000 171,000 136,000 326,000 297,000 142,000             
      third party royalty obligation
    		                                                              1,000,000 500,000 300,000                    
      proceeds from sale of common stock to genzyme
    		                                                           0 0 6,000,000                       
      payment for repurchase of stock options
    		                                                                                    
      issuance of 15,460 and 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2009 and 2008, respectively
    		                                                                                    
      issuance of 15,460 and 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2009 and 2008 respectively
    		                                                                                    
      issuance of 15,460 shares of common stock to fund the company’s 401(k) matching contribution for 2009
    		                                                          65,000                          
      restructuring
    		                                                                        -281,718 0 0 282,000         
      warrant expense for license fees
    		                                                           28,000                         
      amortization of deferred revenue
    		                                                                                    
      increase in patent costs and other assets
    		                                                                                    
      payment to repurchase stock options
    		                                                                                    
      supplemental disclosure for non-cash investing and financing activities:
    		                                                                                    
      issuance of 24,430 shares of common stock to fund the company’s 401(k) matching contribution for 2008
    		                                                                                    
      issuance of 27,660 shares of common stock to fund the company’s 401(k) matching contribution for 2007
    		                                                              1,000                      
      depreciation and write-offs of fixed assets
    		                                                              58,000   66,000 54,000 56,000                 
      proceeds from sale of fixed assets
    		                                                                                    
      issuance of 34,030 shares of common stock to fund the company’s 401(k) matching contribution for 2006
    		                                                                 0                   
      issuance of 56,675 shares of restricted common stock to collaborator in lieu of cash to settle semi-annual license obligation
    		                                                                 0 0 158,000                 
      issuance of 56,675 shares of restricted common stock to collaborators in lieu of cash payments
    		                                                                                    
      issuance of 85,800 shares of common stock to fund the company’s 401(k) matching contribution for 2005
    		                                                                    0                
      increase in restricted cash
    		                                                                                    
      non-cash revenue reduction recorded in connection with warrant extension
    		                                                                        -629,370 0           
      net proceeds from sale of common stock
    		                                                                            0 -78,000 43,383,000     -7,896 
      repayment of notes receivable
    		                                                                           1,000 3,000 342,000 23,000 2,000 1,000 54,000   
      cash and cash equivalents, beginning of year
    		                                                                                    
      cash and cash equivalents, end of year
    		                                                                                    
      repurchase of restricted stock through forgiveness of notes receivable
    		                                                                            2,000 0 83,000      
      forgiveness of notes receivable and accumulated interest
    		                                                                            0 0 228,000      
      supplemental disclosure of non-cash financing activities:
    		                                                                                    
      deferred license fees
    		                                                                                    
      amortization
    		                                                                         275,000 128,000 138,000 144,000 114,000 132,000 234,000 326,000 116,000   
      stock based compensation
    		                                                                           303,000         
      adjustments to reconcile net income to net cash from operating activities –
    		                                                                                    
      non-cash stock-based compensation expense
    		                                                                            154,000 120,000 126,000 329,000   567,801 865,887 
      amortization of deferred licensing fees
    		                                                                                    
      prepaid expenses
    		                                                                                    
      purchase of marketable securities
    		                                                                                    
      maturity and sale of marketable securities
    		                                                                            15,686,000 5,768,000 9,168,000      
      adjustments to reconcile net income to net cash from operating activities
    		                                                                                    
      net sale (purchase) of marketable securities
    		                                                                                    
      purchase of treasury shares
    		                                                                                    
      sale of marketable securities
    		                                                                                10,891,000 3,122,000   
      adjustments to reconcile net income to net cash from operating activities–
    		                                                                                    
      depreciation and amortization expense
    		                                                                                    
      amortization of licensing fees
    		                                                                                    
      non-cash expense associated with issuance of warrants
    		                                                                                    
      interest receivable
    		                                                                                    
      net proceeds from sale of preferred stock
    		                                                                                    
      proceeds from exercise of common stock options and purchase plans
    		                                                                                    
      repayment of stock subscription receivable
    		                                                                                  189,410 3,940 
      sale of restricted stock through issuance of notes receivable
    		                                                                                   -69 
      issuance of warrants to purchase common stock
    		                                                                                    
      purchase of treasury shares through the forgiveness of notes
    		                                                                                    
      equipment purchased through capital lease obligations
    		                                                                                    
      adjustments to reconcile net income to net cash from operating activities—
    		                                                                                    
      proceeds from exercise of common stock options and stock purchase plans
    		                                                                                  65,987  
      repurchase of treasury shares
    		                                                                                    
      adjustments to reconcile net income to net cash from operating activities-
    		                                                                                    
      payments on capital lease bligations
    		                                                                                    
      net proceeds from sale of convertible preferred stock
    		                                                                                    
      adjustments to reconcile net income to net cash from operating activities;
    		                                                                                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.